Sankyo Company, Limited

Kyocera Corporation

Sankko Company, Limited

Masaaki Miyamoto

Norio Nakamura

Takeshi Oshima

Yasuteru Iijima

Nobuyuki Ohkawa

Keisuke Suzuki

Tomio Kimura

Shigeru Ushiyama

Akira Nakao

Akihiro Kawara

Yasuo Noguchi

Hiroyoshi Horikoshi

Toshihiko Fujiwara

Takeshi Kinoshita

Kouhei Furuya

Takeshi Kagasaki

Kiyoshi Hamano

Tomonari Kusunose

Kazuhiko Tanzawa

Nobuo Kuchiki

An HEMSprovided in a consumer having independently operable power supply means (PV, storage battery, PCSand the like) and at least one load, for controlling the power supply means and the load, determines an during-independent-operation schedule that is an operation schedule of the load during the independent operation on the basis of a period when the independent operation is performed, a power supply status of the power supply means, and a status of the load

Control device, power control system, and power control method

Compounds of formula (I) and (II):[wherein R is hydrogen, halogen or alkyl; Ris alkyl, amino or substituted amino; Ris optionally substituted phenyl; Ris hydrogen, halogen or optionally substituted alkyl; Ris hydrogen, optionally substituted alkyl, cycloalkyl, aryl, or aralkyl] have valuable analgesic, anti-inflammatory, anti-pyretic and anti-allergic activities and have the ability to inhibit the production of leukotrienes and to inhibit bone resorption. They are relatively free from the side effects which generally result from the administration of compounds having these kinds of activities.

1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses

Compounds of formula (I) and (II): ##STR1## �wherein R is hydrogen, halogen or alkyl; R.sup.1 is alkyl, amino or substituted amino; R.sup.2 is optionally substituted phenyl; R.sup.3 is hydrogen, halogen or optionally substituted alkyl; R.sup.4 is hydrogen, optionally substituted alkyl, cycloalkyl, aryl, or aralkyl! have valuable analgesic, anti-inflammatory, anti-pyretic and anti-allergic activities and have the ability to inhibit the production of leukotrienes and to inhibit bone resorption. They are relatively free from the side effects which generally result from the administration of compounds having these kinds of activities.

1,2-diphenylpyrrole derivatives, their preparation and their therapeutic

Compounds of formula (I): ##STR1## where R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are hydrogen or alkyl and R.sup.3 is hydrogen, alkyl or various organic groups are effective against osteoporosis at doses at which they also effectively control diabetes.

Treatment and prophylaxis of osteoporosis

A method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma, inflammation or shock by administering an effective amount of a PAF antagonist of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5 ; R.sup.5 is an unsubstituted or substituted C.sub.6 -C.sub.14 carbocyclic aryl of an aromatic heterocyclic having from 5 to 14 ring atoms, of which from 1 to 5 are hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur, the heterocyclic group being unsubstituted or substituted; R.sup.3 is hydrogen, a C.sub.1 -C.sub.6 alkyl, cyano, or --R.sup.5 ; X is oxygen or sulfur; A is a 1,4-piperazin-1,4-diyl or a 1,4-homopiperazin-1,4-diyl; B is a C.sub.1 -C.sub.6 alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl; and R.sup.4 is an unsubstituted or substituted phenyl group.

Method of treating a PAF-mediated pathology or for treating or

Compounds of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 is each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5, wherein R.sup.5 is optionally substituted aryl or aromatic heterocyclic; R.sup.3 is hydrogen, alkyl, cyano or --R.sup.5 ; X is oxygen or sulfur A is 1,4-piperazin-1,4-diyl or a 1,4-homopiperazin-1,4-diyl; B' is alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl: and R.sup.4 is optionally substituted phenyl and pharmaceutically acceptable salts thereof have valuable PAF antagonist activity.

N-acryloylpiperazine compounds

Compounds of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 is each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5, wherein R.sup.5 is optionally substituted aryl or aromatic heterocyclic; R.sup.3 is hydrogen, alkyl, cyano or --R.sup.5 ; X is oxygen or sulfur; A a 1,4-homopiperazin-1,4-diyl; B' is alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl; and R.sup.4 is optionally substituted phenyl and pharmaceutically acceptable salts thereof have valuable PAF antagonist activity, and may be prepared by reacting a compound containing the homopiperazine part of the molecule with a compound containing the other part of the molecule.

N-acryloylpiperazine derivatives, their preparation and their use of PAF

Compounds of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 is each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5, wherein R.sup.5 is optionally substituted aryl or aromatic heterocyclic; R.sup.3 is hydrogen, alkyl, cyano or --R.sup.5 ; X is oxygen or sulfur; A is 1,4-piperazin-1,4-diyl or a 1,4-homopiperazin-1,4-diyl; B' is alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl; and R.sup.4 is optionally substituted phenyl and pharmaceutically acceptable salts thereof have valuable PAF antagonist activity, and may be prepared by reacting a compound containing the piperazine or homopiperazine part of the molecular with a compound containing the other part of the molecule.

N-acryloylpiperazine derivatives, their preparation and their use as PAF

A new compound, which we have named 'Leualacin' has the formula (I): ##STR1## and may be prepared by cultivation of a microorganism of the genus Hapsidospora, especially Hapsidospora irregularis. The compound may be used for the treatment and prophylaxis of cardiovascular diseases and disorders, especially hypertension.

Growing community of inventors

Tokyo, Japan

Masaaki Miyamoto